Clinical Trial
doi: 10.1136/hrt.40.10.1069.
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators
- PMID: 361054
- PMCID: PMC483536
- DOI: 10.1136/hrt.40.10.1069
Item in Clipboard
Clinical Trial
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators
Br Heart J.
1978 Oct.
No abstract available
Similar articles
-
The clofibrate trial--the lipid hypothesis retested.Med J Aust. 1979 Jun 2;1(11):490-1. Med J Aust. 1979. PMID: 381862 Clinical Trial. No abstract available.
-
[Real or alleged risks of clofibrate derivatives and certain risks of their prohibition].Nouv Presse Med. 1979 Mar 31;8(15):1223-5. Nouv Presse Med. 1979. PMID: 375186 Clinical Trial. French. No abstract available.
-
Cholesterol, clofibrate and ischaemic heart disease. Facts and emotions around.Cor Vasa. 1979;21(6):377-9. Cor Vasa. 1979. PMID: 397875 Clinical Trial. No abstract available.
-
Hypolipaemic drugs and coronary heart disease.J Clin Pathol Suppl (R Coll Pathol). 1975;9:106-14. J Clin Pathol Suppl (R Coll Pathol). 1975. PMID: 783209 Free PMC article. Review. No abstract available.
-
Does hypolipidemic therapy prevent coronary heart disease?Cardiovasc Clin. 1974;6(2):1-8. Cardiovasc Clin. 1974. PMID: 4374303 Review. No abstract available.
Cited by
-
Clofibrate raises human 24 h intragastric acidity but does not affect plasma gastrin concentration.Br J Clin Pharmacol. 1990 Apr;29(4):473-7. doi: 10.1111/j.1365-2125.1990.tb03666.x. Br J Clin Pharmacol. 1990. PMID: 2328195 Free PMC article.
-
Lessons learned from the prospective pravastatin pooling project.Curr Atheroscler Rep. 2004 Sep;6(5):366-74. doi: 10.1007/s11883-004-0048-z. Curr Atheroscler Rep. 2004. PMID: 15296703 Review.
-
Adverse effects of hypolipidaemic drugs.Med Toxicol. 1987 Jan-Feb;2(1):10-32. doi: 10.1007/BF03259858. Med Toxicol. 1987. PMID: 3547004 Review.
-
Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics.Br J Clin Pharmacol. 2003 Jul;56(1):84-91. doi: 10.1046/j.1365-2125.2003.01818.x. Br J Clin Pharmacol. 2003. PMID: 12848779 Free PMC article.
-
Niacin or ezetimibe for patients with, or at risk of coronary heart disease.Clin Med Insights Cardiol. 2010 Oct 31;4:99-110. doi: 10.4137/CMC.S5970. Clin Med Insights Cardiol. 2010. PMID: 21079754 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
